Press release Warsaw, 20/04/2015

**Celon Pharma S.A. is searching for a drug to treat Alzheimer's disease**

**The scientific-business consortium established with the Jagiellonian University Medical College, the Institute of Pharmacology of the Polish Academy of Sciences in Cracow and Celon Pharma S.A. received over PLN 4 million for implementation of the "New anti-amyloid therapy for cognitive disorders" (NATco) project.**

The project entails the development of a new pro-cognitive drug which would be used in the treatment of i.a. Alzheimer's disease. In cooperation with scientific institutions located in Cracow, Celon Pharma S.A. will play the strategic role of an industrial partner. The company will be responsible not only for the research work, but also for potential commercialisation of the drug.

on 17 April, the Jagiellonian University Medical College, acting as the consortium leader, signed the final contract with the National Centre for Research and Development on implementation of the NATco project. Additionally, at the beginning of February this year, a consortium agreement was signed, which not only specified the division of tasks, but also determined the composition of the Project Steering Committee, which includes:   
Paweł Zajdel, PhD (the Jagiellonian University Medical College), prof. Andrzej Bojarski (IF PAN), as well as Maciej Wieczorek, PhD and Mikołaj Matłoka from Celon Pharma S.A.The Centre for Technology Transfer of the Jagiellonian University (CITTRU) helped determine the rules of operation of the consortium and prepare the agreement.

The total value of the project is PLN 4,815,143 of which PLN 4,100,000 comes from the National Centre for Research and Development.

The funds were obtained due to a positive decision regarding an application submitted for a competition organised under the Applied Research Programme. The objective of the Applied Research Programme is to strengthen cooperation between research institutes and entrepreneurs interested in applying research results into their economic activities.

---------------------------------------------------------------------------------------

**Celon Pharma S.A.** is an integrated Polish pharmaceutical company founded in 2002 by Maciej Wieczorek, PhD. Its portfolio includes specialised prescription drugs for patients with schizophrenia, hypertension, central nervous system disorders, breast cancer, as well as drugs used in treatment of human immunodeficiency virus (HIV) infections. The company has state-of-the-art research and development laboratories, where it develops both generic and innovative drugs used in treatment of oncological, neuropsychiatric, metabolic and inflammatory diseases.

**More information can be obtained by contacting:**  
Katarzyna Zalega

Celon Pharma S.A. Press Office

662 061 079

[k.zalega@onboard.pl](mailto:k.zalega@onboard.pl)